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Abstract: The dopamine transporter (DAT) imaging provides an objective tool for the assessment of dopaminergic function of presynaptic
terminals which is valuable for the differential diagnosis of parkinsonian disorders related to a striatal dopaminergic deficiency from
movement disorders not related a striatal dopaminergic deficiency. DAT imaging with single-photon emission computed tomography
(SPECT) can be used to confirm or exclude a diagnosis of dopamine deficient parkinsonism in cases where the diagnosis is unclear.
It can also detect the dopaminergic dysfunction in presymptomatic subjects at risk for Parkinson’s disease (PD) since the reduced
radiotracer binding to DATs in striatum is already present in the prodromal stage of PD. This review covers the rationale of using DAT
SPECT imaging in the diagnosis of PD and other parkinsonian disorders, specifically focusing on the practical aspects of imaging and
routine clinical indications.
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1. Introduction
Parkinson’s disease (PD) is characterized by the
progressive loss of dopaminergic neurons in the pars
compacta of the substantia nigra [1,2]. Although the
pathophysiologic mechanisms remain unclear, PD is
a neurodegenerative disease that results in decreased
striatal dopamine production and causes the symptoms
of parkinsonism (rigidity and bradykinesia) when 60%–
80% of the presynaptic dopaminergic neurons are lost
[2,3]. The dopamine transporter (DAT) proteins, which
are found in the membrane of presynaptic endings of
dopaminergic neurons and responsible for the reuptake
of dopamine from the synaptic cleft, reflect the degree of
presynaptic dopaminergic neuron loss and may be used
as a diagnostic biomarker of PD [1,2,4]. The level of DAT
expression in the striatum (caudate and putamen) can be
evaluated by several tropane-based radiotracers, among
which iodine-123 (123I)-FP-CIT (123I-ioflupane) and
123I-beta-CIT are the commercially available and the most
commonly used ones [5–7]. Brain single-photon emission
tomography (SPECT) is the modality to assess DAT
expression in the striatum. Positron emission tomography
(PET) radiotracers for DAT imaging [such as fluorine-18
(18F)-FP-CIT] are also present, however, none of them are
commercially available yet [4].

The differential diagnosis of PD involves a mixed group
of diseases which are collectively called as parkinsonian
syndromes and may be functionally divided into two
groups: In the first group are the parkinsonian disorders
related to a striatal dopaminergic deficiency which
include the neurodegenerative atypical parkinsonism
syndromes, namely multiple system atrophy (MSA),
progressive supranuclear palsy (PSP), cortical-basal
ganglionic degeneration (CBD), and Lewy body dementia
(LBD) [4]. The other group involves movement disorders
that are not related to a striatal dopaminergic deficiency,
such as essential tremor (ET), adult-onset dystonic
tremor, secondary parkinsonism (due to dopamine
receptor blocking drugs and pallidal toxins), vascular
parkinsonism, normal pressure hydrocephalus and
psychogenic parkinsonism [4]. Therefore, DAT SPECT
imaging may be useful for the differential diagnosis of
parkinsonism by providing evidence for or ruling out the
presence of striatal dopaminergic deficiency [1,2,4–9]. In
clinical practice, DAT SPECT imaging may contribute to
clinical management of patients who do not fully meet the
diagnostic criteria of PD or who have atypical findings, do
not give an adequate response to treatment and show mild
symptoms at an early stage.
Both presynaptic and postsynaptic functions of the
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dopaminergic neurotransmitter system can be evaluated
with nuclear medicine methods. While presynaptic
dopaminergic imaging is used to investigate the presence of
a neurodegenerative process in the dopaminergic system,
postsynaptic dopaminergic imaging is mostly used to make
a differential diagnosis of PD with the neurodegenerative
atypical parkinsonism syndromes [1,2,4–10]. However,
the clinical uses of postsynaptic D2-receptor imaging
with SPECT or PET are not common today. In addition
to the limited availability of D2-receptor radiotracers,
the widely available brain 18F-fluorodeoxyglucose
(FDG) PET imaging has a higher diagnostic accuracy
than postsynaptic D2-receptor SPECT imaging in the
differential diagnosis of PD with the neurodegenerative
atypical parkinsonism syndromes [11]. Myocardial
scintigraphy of 123I-metaiodobenzylguanidine (mIBG)
is another method with high diagnostic accuracy in the
differential diagnosis of PD with the neurodegenerative
atypical parkinsonism syndromes (MSA, PSP, and CBD)
[12].
DAT SPECT studies were carried out in the Gazi
University Hospital for the first time in our country within
the scope of the multicenter ENC-DAT project launched
in 2009 by the European Association of Nuclear Medicine
(EANM) neuroimaging committee. The project aimed to
create a normative 123I-ioflupane SPECT database [13–
17]. Then, the first clinical routine DAT SPECT studies
in our country were carried out in our center. Today, as
the clinicians’ awareness of this practice is increasing,
DAT SPECT studies are becoming widespread in our
country. Therefore, we aimed to share our experience and
summarize the practical aspects and the clinical role of

DAT SPECT imaging in the evaluation of patients with
parkinsonism in this review.
2. Practice of DAT imaging
2.1. Radiotracers
The basic structure of a radiotracer is composed of a
bioactive molecule that binds to the molecular target
and a radionuclide that can be detected by the SPECT
or PET camera. The most commonly used radionuclides
for SPECT imaging are 123I and technetium-99m
(99mTc) that both emit gamma rays of low-energy and
have physical half-lives of approximately 13 and 6 h,
respectively. Due to the higher target binding ratios and
the presence of quantitative analysis tools that include
normal reference data, the DAT radiotracers that are
labeled with 123I, especially 123I-ioflupane, are generally
preferred for presynaptic dopaminergic imaging [5–9].
The PET radiotracers for dopaminergic imaging are
radiolabelled with 18F or carbon-11 (11C) that have 110
and 20 min of physical half-lives, respectively. Since the
physical half-lives of PET radiotracers are relatively short
and the production costs are higher when compared to
SPECT radiotracers, their use is mostly limited to research
centers with cyclotron facilities.
In vivo measurement of DAT availability is possible by
using several DAT specific SPECT and PET radiotracers
(Table 1) [5–9]. DAT is among the several targets in the
striatal dopaminergic system that can be studied with
nuclear medicine methods. The alternative radiotracers
target the aromatic-L-amino acid decarboxylase (AADC)
enzyme in the presynaptic dopaminergic neuron and the
vesicular monoamine transporter protein 2 (VMAT2)

Table 1. The SPECT and PET radiotracers used for the evaluation of striatal dopaminergic neurotransmission in PD and parkinsonian
disorders [4–8, 10].
Molecular target in the striatum

SPECT radiotracers

PET radiotracers

99mTc-TRODAT,
123I-altropane,
123I-beta-CIT,
123I-FP-CIT
(ioflupane)

18F-FP-CIT,

Common indications

Presynaptic dopaminergic terminal

DAT

11C-PE2I,
18F-FE-PE2I
11C-DTBZ,

VMAT2

Evaluation of functional integrity of striatal
dopaminergic neurons in patients with clinically
uncertain parkinsonian syndromes

18F-FP-DTBZ

AADC

18F-fluorodopa

Postsynaptic dopaminergic nerve
D2 receptors

123I-IBZM

11C-raclopride,
18F-fallypride,
18F-DMFP

Differential diagnosis of parkinsonian syndromes (PD
vs. MSA, PSP and CBD)
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in the membrane of presynaptic dopaminergic neuron’s
storage vesicles. Dopamine is produced as a result of a
two-step synthesis using L-tyrosine in the presynaptic
dopaminergic neuron: In the first step, L-dopa is formed
by hydroxylation of L-tyrosine and in the second step
dopamine is formed by the effect of AADC on L-dopa.
This dopamine is then stored in vesicles at the presynaptic
neuron terminal via the VMAT2. When the presynaptic
dopaminergic neuron is stimulated, the dopamine in the
vesicles is discharged into the synaptic space. Dopamine
in the synaptic space can be taken back into the cell by
the DAT in the membrane of the presynaptic neuron.
For the imaging of postsynaptic dopaminergic neurons,
several radiotracers that target dopamine receptors (D1, D2-receptors) are also available [10]. Since more than
90% of D2-receptors are found in the postsynaptic cell,
radiotracers that bind to D2-receptors are used to evaluate
the functions of these cells [10].
Among the various SPECT and PET radiotracers
for the functional imaging of the dopaminergic system,
only 123I-ioflupane and 123I-beta-CIT have received
both the U.S. Food and Drug Administration (FDA) and
the European Medicines Agency (EMA) approvals. An
alternative for DAT SPECT imaging is PET imaging with
18F labeled fluorodopa. Although the 18F-fluorodopa has
been approved by EMA, it has not yet been approved by the
FDA for production and commercial distribution. None of
the other radiotracers used in dopaminergic imaging has
yet gone through the aforementioned approval processes.
In Turkey, 123I-ioflupane is currently the only radiotracer
that is approved by the Turkish Medicines and Medical
Devices Agency of the Ministry of Health. Today, DAT
SPECT study is the most commonly used molecular
imaging method in parkinsonian disorders due to the

presence of long-term clinical experience, normative data
that have been created, and the practice guidelines which
were prepared by several medical specialty associations
[5–9, 17–22].
2.2. Patient preparation
Patients should avoid taking any drugs or other
psychotropic substances which may significantly influence
the DAT binding of radiotracers before the investigation
(Table 2) [5,6,8]. The recommended withdrawal period is
at least five times the drug’s biological half-life [5,6,8,23].
The antiparkinsonian medications (such as L-dopa,
dopamine agonists, NMDA receptor blockers, MAO-B,
and COMT inhibitors) do not need to be stopped since
they do not significantly affect DAT binding [5,6,8,23].
A recent metaanalysis showed that the striatal DAT
availability was decreased in cocaine, amphetamine, and
methamphetamine users [24]. In the same metaanalysis,
it was shown that smoking does not cause a significant
difference in striatal DAT availability. Regarding sedatives,
another metaanalysis showed that opioid users had a
significantly lower DAT availability and alcohol users had
no significant difference in DAT availability [25]. Other
drug groups that may alter DAT binding of radiotracers
include opioid derivatives (fentanyl, modafinil), central
nervous system stimulants (ephedrine, phentermine),
amphetamines
(methylphenidate),
antidepressants
(bupropion, mazindol, radafaxine), adrenergic agonists
(norepinephrine, phenylephrine), anticholinergic drugs
(benztropine), and anesthetics (isoflurane, ketamine,
phencyclidine) [5,6,8,23,24]. Besides, selective serotonin
reuptake inhibitors may slightly increase the binding of
radiotracers to DAT [26,27]. These effects, which should
be taken into consideration in clinical trials, do not make
a difference in clinical routine practices to the extent that

Table 2. Drugs or other psychotropic substances that can significantly affect radiotracer binding in the DAT SPECT study [5–8, 23–26].
Drug class

Drug names

Cocaine

CNS stimulants

Cocaine
striatal 123I-ioflupane binding
Amphetamine, methamphetamine,
striatal 123I-ioflupane binding
methylphenidate
Phentermine, ephedrines
striatal 123I-ioflupane binding

Opioid derivatives

Fentanyl, modafinil

Antidepressants

Bupropion, mazindol, radafaxine

Amphetamines

Adrenergic agonists
Anticholinergic drugs
Anesthetics
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Potential effects

striatal 123I-ioflupane binding

striatal 123I-ioflupane binding
striatal 123I-ioflupane binding. This effect occurs especially when
Norepinephrine, phenylephrine
infused at high doses
striatal 123I-ioflupane binding. Other anticholinergic drugs
Benztropine
striatal 123I-ioflupane binding to a degree that does not affect visual
evaluation
Isoflurane, ketamine, phencyclidine striatal 123I-ioflupane binding
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they affect the patient’s imaging results [23]. Cholinesterase
inhibitors and neuroleptics also do not affect the DAT
binding of radiotracers [23].
It is necessary to minimize free 123I accumulating
in the thyroid gland by blocking the thyroid gland with
Lugol solution (equivalent to 100 mg iodide) or potassium
perchlorate (600 mg) at least 1 h before radiotracer
injection [5–9]. In patients who are sensitive to any of these
products, the use of these products should be avoided.
Even in the absence of a blocking agent, the radiation dose
to which the thyroid is exposed will be low [9]. In some
patients, an antiallergic premedication can be given before
the procedure. However, iodine allergy in the patient is not
a contraindication for radiotracer administration.
Pregnancy is a contraindication for the DAT SPECT
study. Breastfeeding is a relative contraindication and
patients should discontinue breastfeeding for 6 days after
they receive the 123I labeled radiotracer. Fasting is not
required and patients should be encouraged to be well
hydrated on the day of examination to minimize bladder
radiation exposure since the radiotracer is excreted in the
urine.
It is necessary to control and ensure that the patient
will be able to cooperate and lie still for approximately 40
to 60 min during the investigation. If sedation is required,
it should not be given earlier than 1 hour before the SPECT
acquisition.
2.3. Safety of DAT imaging
In adults, the recommended dose is 110–250 MBq
(usually 185 MBq) for 123I-labeled DAT radiotracers.
The radiotracer will be delivered ready to use and should
be injected within the time period specified by the
manufacturer, usually on the day of delivery. Radiotracer
is injected in the form of a slow i.v. bolus that lasts about
20 s.
A radiotracer dose of 185 MBq will cause an effective
dose of approximately 4.4 mSv in an adult patient [9]. This
radiation dose is higher in comparison to radiographic
examinations (with average effective doses of 0.1–1.5
mSv) and lower in comparison to a chest computerized
tomography examination (with an average effective dose
of 8 mSv) [28]. Bladder wall (organ receiving the highest
radiation dose) will be exposed to a radiation dose of
approximately 1.0 rad [9].
In a safety analysis of clinical studies that involved
more than a thousand patients, mild side effects such
as headache, nausea, dizziness, nasopharyngitis, and
development of hematoma at the injection site were
observed in less than 4% of patients after 123I-ioflupane
injection [29]. No serious adverse effects were observed
related to 123I-ioflupane administration and the
radiotracer was well tolerated.
There is no established clinical indication for DAT

SPECT for children and the safety of the use of these
radiotracers in pediatric patients has not been established.
The effect of kidney or liver failure on DAT SPECT
imaging is unknown. Since I-123 FP-CIT is excreted by
the kidneys, patients with severe renal impairment may
have an increased dose of radiation and a possible change
in DAT SPECT images [9,29].
2.4. SPECT imaging
SPECT imaging should be carried out by or under the
supervision of nuclear medicine physicians. It is preferable
to perform DAT examination on SPECT cameras with
multiple detectors. Single-detector SPECT systems are
not recommended, since acquiring sufficient counts will
require long imaging times, which may make examination
difficult for the patient and cause movement artifacts [5–
9].
The recommended imaging time for 123I-ioflupane is
3 to 6 h after the radiotracer injection. For 123I-beta-CIT,
this period is 18 to 24 h after injection. It is recommended
to standardize imaging times in a center (for example, 3
h after injection for 123I-ioflupane) so that images of
different patients or follow-up images of a patient will be
more comparable by excluding time-dependent changes in
radiotracer uptake in the brain [5–9].
The distribution of DAT radiotracers in the brain is
not affected by functional activations. Therefore, patients
do not need to remain in a quiet/dim environment before
and during the injection of the radiotracer. Similarly, there
are no dietary restrictions for the DAT SPECT study. If
the patient has claustrophobia or if the patient is unable
to lie still in the camera, a short acting benzodiazepine
(sedative) can be given before imaging [5–9].
Technical specifications on how to perform DAT
SPECT imaging are excluded from the scope of this article
since they can be found in detail in the current procedure
guidelines [5–9]. Some important practical issues related
to DAT SPECT imaging are as follows: DAT SPECT
imaging will take approximately 30–40 min on a twodetector gamma camera. The acquired projection images
should be reviewed in terms of patient motion before
image processing. Given the limited spatial resolution
(about 8–10 mm) of SPECT images, small amounts of
patient motion can be tolerated. However, if the patient
is observed to move significantly, it is recommended to
repeat the imaging. Iterative reconstruction methods are
generally preferred for obtaining cross-sectional SPECT
images from the projection data since physical corrections
(such as attenuation, scatter corrections) can be added to
the reconstruction algorithm. Also, when using normal
databases for semiquantitative evaluation of DAT SPECT
images, care should be taken to match the reconstruction
parameters with the parameters which were used to create
the normal database. Performing physical corrections
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improves the accuracy of quantitative analysis and can
significantly affect the values obtained from quantitative
analysis [14]. In general, SPECT systems are subjected to
routine quality control procedures within the framework
of a quality control program. Besides, imaging of an
anthropomorphic striatal brain phantom by applying the
routine clinical imaging and processing parameters used
in DAT SPECT studies can be useful to assess the system’s
overall SPECT image quality.
3. Assessment of DAT SPECT images
The assessment of DAT binding in striatum depends on
visual interpretation of SPECT images and the results of
quantitative analysis of SPECT data, if available. The visual
assessment aims to decide whether the DAT binding is
normal or abnormal. If DAT binding is abnormal, the
degree of decrease in DAT binding in striatal subregions
regarding left-to-right asymmetry and posterior-toanterior uptake ratio (gradient) should be evaluated [5,
6]. Given the age-dependent decrease of striatal DAT
binding in normal populations, quantitative analysis of
DAT SPECT is strongly recommended for an objective
assessment [5, 6]. In clinical trials, quantitative analysis
is often used to measure DAT intensity as it has high
reproducibility and objectivity to determine the degree of
disease and response to treatment [14,26,30,31]. In various
studies, it has been shown that the inclusion of quantitative
analysis results in the image evaluation process of readers
increases the diagnostic performance [15, 30–32].
3.1. Visual assessment
When preparing DAT SPECT images for visual evaluation,
it is recommended to determine the axial plane in a
standard way which is parallel to the line passing between
the anterior and posterior commissures. DAT SPECT
images should be evaluated on the computer screen
since the color scale and contrast can be manipulated
by the reader. In the presence of an anatomical lesion
and cerebral atrophy, the location or shape of striatal
structures may change. Therefore, when evaluating DAT
SPECT images, computed tomography (CT) and magnetic
resonance imaging (MRI) findings should be taken into
account. Brain MRI findings can also help assess vascular
comorbidity [9].
It has been shown in various studies that experienced
readers can read DAT SPECT images with high accuracy
only by visual evaluation [20,30,33,34]. Visual evaluation
is usually sufficient to evaluate striatal left-to-right
asymmetry and differential radiotracer uptake in striatal
subregions. In axial sections, normal striatum should
be in the form of a comma and its borders should be
clearly visible (Figure 1a). A slight asymmetry in striatal
radiotracer uptake may be seen in normal individuals.
The findings of quantitative analysis may be useful when
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evaluating the degree of striatal asymmetry. In addition,
the level of striatal radiotracer uptake should be compared
with background activity. A good contrast is expected
between the striatal and the background signals. However,
there is some decrease in striatal radiotracer uptake in both
caudate and putamen with normal aging. In this regard,
quantitative analysis can help the reader in evaluating the
findings.
Decreasing striatal radiotracer uptake and increasing
background activity in DAT SPECT images is an indicator
of decreased presynaptic dopaminergic function. Striatal
involvement can occur unilaterally or bilaterally. In
PD, the most prominent decrease of radiotracer uptake
occurs in the dorsal putamen contralateral to the side
where neurological findings are more evident. With the
progression of the disease, the involvement of anterior
putamen and then the caudate nucleus becomes more
evident. Although this posterior-to-anterior gradient is
also seen in the later stages of the disease, it is more evident
in the early stages [1,33]. Since putamen is often more
severely affected in early-stage PD (such as in patients with
premotor or hemiparkinsonism findings), the striatum
typically has an oval or circular appearance on DAT
SPECT images (Figure 1b) [18,33,35,36]. Background
activity increases more as a result of disease progression
and decreasing striatal radiotracer uptake (Figure 1c).
DAT SPECT imaging has a high sensitivity in the early
stages of PD and the high negative predictive value is an
important advantage of this method [30,33]. Indeed, in
a controversial group of patients named SWEDD (scan
without evidence of dopaminergic deficit), who were
clinically diagnosed with PD but had normal DAT SPECT
scans, the findings did not change during the clinical
follow-up and patients did not show progression [37,38].
This observation indicates that the specificity of DAT
SPECT imaging for early-stage PD may be higher than the
clinical evaluation.
In patients with PD, the levels of DAT binding
measured with PET or SPECT will overestimate the true
degree of neurodegeneration in the striatum because of
a downregulation of DAT expression in the remaining
neurons as an adaptive mechanism to preserve synaptic
dopamine levels [39,40]. On the contrary, the AADC
expression as shown by 18F-fluorodopa PET imaging
will underestimate the true degree of neurodegeneration
because of its upregulation [39,40]. Therefore, in early
PD, the striatal dysfunction indicated by DAT SPECT is
more pronounced than the dysfunction observed with
18F-fluorodopa PET [40]. However, in studies comparing
these two methods in the same patients, both methods had
high accuracy in differentiating PD patients from healthy
controls [41,42]. There is a correlation between the degree
of motor impairment (Unified Parkinson’s Disease Rating
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Figure 1. Axial 123I-ioflupane DAT SPECT images of three different patients with parkinsonism. (a) Striatal radiotracer uptake
is visually symmetrical and normal. The background activity is low. Both striata have comma shape and sharp borders. The
findings of the quantitative analysis were in normal ranges. These findings exclude the presence of a striatal dopaminergic
deficiency. (b) Radiotracer uptake in putamen is bilaterally decreased and background activity is slightly increased. Both striatal
structures took an oval appearance. Specific binding ratios calculated from both putamens were significantly lower than the
patient’s age group. The asymmetry index was 25%. Specific binding ratios calculated from the caudate nuclei were also lower
than the mean values determined

for the patient’s age group, but this difference was not statistically significant (within the 95%
confidence interval). These findings indicate a moderate nigrostriatal dopaminergic neuron loss and the pattern of involvement
may be consistent with early-stage PD. (c) Striatal radiotracer uptake is decreased and background activity is increased
significantly. Specific binding ratios calculated from both putamens and caudate nuclei are significantly lower than the patient’s
age group. These findings indicate a severe degree of nigrostriatal dopaminergic neuron loss and the pattern of involvement may
be consistent with late-stage PD.

Scale motor scores, Hoehn and Yahr stage scores) in early
stage PD and the degree of striatal involvement in DAT
SPECT imaging [40,43]. This correlation disappears in
the later stages of the disease as the DAT SPECT findings
reach saturation [36].
In patients with LBD, the caudate nuclei show early
involvement which may cause the gradient between
the putamen and caudate to be less pronounced than in
patients with PD [20,30]. Similarly, the involvement of the
anterior striatum is seen earlier and more prominently in
parkinsonian type MSA and PSP compared to PD [40,44].
DAT function in cerebellar type MSA is higher when
compared to parkinsonian type MSA [40]. Patients with
CBD show a marked asymmetric striatal involvement (both
in the caudate nucleus and in the putamen) contralateral
to the body side where clinical findings are more evident
[45]. However, it should be kept in mind that there is a
significant overlap between PD and neurodegenerative
atypical parkinsonism syndromes in terms of DAT
SPECT findings, and this examination alone may not be
sufficient for differential diagnosis [20,30]. In order to
make this distinction, postsynaptic D2-receptor imaging,

18F-FDG PET (Figures 2a and 2b), or cardiac 123I-mIBG
SPECT studies can be performed (Figures 3a and 3b)
[11,12,46]. In clinical situations such as ET, drug-induced
parkinsonism, vascular parkinsonism, and psychogenic
parkinsonism DAT SPECT findings are normal; and
therefore, differential diagnosis of these clinical conditions
from neurodegenerative parkinsonian syndromes can be
made by DAT SPECT examination [4,33,47].
DAT SPECT findings are more difficult to evaluate for
the diagnosis of vascular parkinsonism. Vascular lesions
in the basal ganglia are common, especially in the elderly.
However, these vascular lesions cause parkinsonism in a
small number of patients. If the infarct does not directly
involve striatal structures, the striatal DAT radiotracer
uptake is usually normal or slightly reduced. A striatal infarct
causes a sharply demarcated photopenic appearance in the
DAT SPECT images which differs from the findings that are
usually seen in neurodegenerative parkinsonian syndromes
in terms of quality and morphological appearance.
Evaluation of the DAT SPECT findings together with a
recent brain MRI examination of the patient may assist the
reader in making this distinction [48,49].
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Figure 2. Axial 123I-ioflupane DAT SPECT and brain 18F-FDG PET images of a patient with suspected
neurodegenerative parkinsonism. (a) In the 123I-ioflupane DAT SPECT examination radiotracer uptake in basal ganglia
is bilaterally decreased and background activity is slightly increased. Both striatal structures took an oval appearance.
Specific binding ratios calculated from both putamens and caudate nuclei were significantly lower than the patient’s age
group. The decrease in uptake was more prominent in left basal ganglion and asymmetry indices were 10% and 37%
for putamen and caudate nucleus, respectively. (b) The axial brain 18F-FDG PET and T1-weighted MR images which
were simultaneously acquired on a hybrid PET-MR camera showed bilateral relatively increased putaminal glucose
metabolism and normal findings in the cerebral cortex which is defined as a metabolic marker for PD on brain 18F-FDG
PET [46]. MR examination did not show a specific pathological change. Taken together, these findings supported the
diagnosis of PD in this patient.

Figure 3. Axial 123I-ioflupane DAT SPECT and planar cardiac 123I-MIBG images of a patient with suspected neurodegenerative
parkinsonism. (a) In the 123I-ioflupane DAT SPECT examination radiotracer uptake in basal ganglia is bilaterally decreased and
background activity is slightly increased. Both striatal structures took an oval appearance. Specific binding ratios calculated from both
putamens and caudate nuclei were significantly lower than the patient’s age group. The decrease in uptake was more prominent in
left basal ganglion and asymmetry indices were 13% and 10% for putamen and caudate nucleus, respectively. The patient had clinical
findings of parkinsonism and autonomic dysfunction and the presumed diagnosis was PD or MSA. Although DAT SPECT findings
verified the presence of a striatal dopaminergic neurodegeneration, it was not adequate for making a differential diagnosis between
PD and MSA. Therefore, a cardiac 123I-MIBG examination was requested. (b) The planar cardiac 123I-MIBG image displays normal
radiotracer uptake in the left ventricle. Since cardiac 123I-MIBG uptake is expected to be decreased in PD and normal in MSA, these
findings supported the diagnosis of MSA in this patient [12].
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The differential diagnosis of LBD from Alzheimer’s
disease (AD) can be done with high accuracy using DAT
SPECT imaging [20]. While striatal binding of DAT
radiotracer is usually normal or slightly low in AD, it is
significantly decreased in LBD [20, 50]. DAT SPECT is
included as a biomarker in the diagnostic criteria of LBD due
to its approximately 20% higher specificity in comparison
to clinical diagnosis [20]. However, approximately 10% of
patients who meet the pathological criteria of LBD may
experience normal DAT SPECT findings. DAT SPECT
becomes abnormal in these patients usually within 1.5
years [51]. This finding has been associated with the
heterogeneous topographic accumulation of α-synuclein
in the brain: While a low-grade of α-synuclein pathology
in substantia nigra was observed in these LBD patients,
they had a higher grade of α-synuclein pathology in
neocortical regions [50].
3.2. Quantitative assessment
The most commonly used quantitative analysis method
in both research and clinical routine is the calculation
of the ratio of striatal radiotracer uptake to background
activity (Specific binding ratio = (striatal counts–
background counts)/background counts) [5–9, 31]. For
this purpose, regions of interest around the striatum and
its subregions (caudate nucleus, putamen) need to be
created. The background activity is generally measured
from the cerebellum or the occipital cortex. Although
the specific binding ratio is related to DAT density, it is
not a parameter that directly reflects DAT density or the
number of presynaptic neurons. Many biological and
technical variables (age and sex of the patient, drugs
used by the patient, patient’s movement during imaging,
physical characteristics of the camera, variables related to
SPECT imaging and processing of images, quantification
algorithm, and the region of interest used) may affect
this ratio [14,15,24,25]. Regions of interest can be created
according to the anatomical boundaries of striatal
structures, and smaller areas of interest can be used to
measure from caudate nuclei, anterior and posterior
putamen [52,53]. They can be drawn by hand or to reduce
operator-dependent variability quantitative analysis tools
that automatically draw the regions of interest can be used
[52,54–57]. Additionally, brain CT and MRI images can be
used to determine the boundaries of the basal ganglia and
to create regions of interest [58]. The use of radiological
images for this purpose may be especially useful in cases
where automatic analysis methods are not used and the
striatal radiotracer uptake is very low. Moreover, in order
to interpret the patient’s quantitative data correctly, it
is necessary to compare them with a normal database
that preferably contains age appropriate reference values
[17,21].

In addition to the specific binding ratios for caudate
and putamen, different quantitative variables such as leftto-right asymmetry values [Asymmetry index = (Left–
Right) / (Left+Right)] and putamen-to-caudate ratios
can also be calculated from DAT SPECT images. These
quantitative parameters may be useful in patients where it
is difficult to evaluate images and where a clear evaluation
cannot be made. In particular, the putamen/caudate ratio
is an important data since it is independent of the imaging
variables, reconstruction algorithm, and background
activity. Similarly, assessment of asymmetry between the
right and left nuclei is useful for detecting early-stage
disease, but mild (less than 6%) asymmetry may also occur
in the striatum or striatal subregions of healthy individuals
[52].
All variables obtained as a result of the quantitative
analysis of DAT SPECT images depend on the imaging
method used, the reconstruction algorithm, and the
corrections applied. Therefore, there are no absolute
normal values that can be used in all conditions. Ideally,
each center should image a healthy control group and
generate their own normal reference values. However,
since striatal DAT density varies depending on age and
sex, it is generally preferred to use existing normal DAT
SPECT databases and to match the method used for
DAT SPECT imaging to the method used in the creation
of these databases. To evaluate the performance of this
matching process systematically, it is suggested to scan
an anthropomorphic striatal phantom and to determine
the quantitative analysis results of the system for different
levels of specific striatal radiotracer uptake values [13,16].
There are two large normal databases that can be
used in quantitative analysis of DAT SPECT images. The
first one is the output of the ENC-DAT study that was
launched by the EANM Neuroimaging committee in 2009
and included a single center from Turkey (Gazi University
Hospital) among 13 different European centers [13–17]. In
this study, 123I-ioflupane DAT SPECT data were recorded
from 139 healthy control subjects (74 males, 65 females;
age range 20–83 years, mean age 53 years). The second
normal 123I-ioflupane DAT SPECT database was obtained
in the PPMI (Parkinson’s progression marker initiative)
project [21]. These two studies have shown that the striatal
uptake of this radiotracer decreases approximately 5.5%–
6.0% (0.6%/year) in each 10-year period with normal
aging and the specific binding ratios differ depending on
sex. In the PPMI study, it was observed that radiotracer
uptake in all striatal regions decreased significantly in the
4-year follow-up of patients diagnosed with PD [21]. This
decrease occurs approximately 20 times faster than the
decrease observed in normal aging. These results suggest
that DAT SPECT imaging may be a suitable biomarker for
demonstrating PD progression.
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4. Conclusion
In patients with suspected PD or other parkinsonian
disorders, DAT SPECT imaging be used to evaluate the
functional integrity of presynaptic striatal dopaminergic
neurons. DAT SPECT is a valuable tool for the early
diagnosis of PD and for the differential diagnosis of PD
from other nondegenerative causes of parkinsonism.
Normal DAT SPECT findings exclude presynaptic striatal
dopaminergic insufficiency. Thus, the clinical findings of
parkinsonism in these patients may be related to clinical
conditions such as ET, drug-induced parkinsonism,
psychogenic parkinsonism or vascular parkinsonism.
Abnormal DAT SPECT findings indicate a variety of
diseases that have presynaptic striatal dopaminergic

insufficiency as a common pathophysiological process,
including PD, MSA, PSP, CBD, and LBD. If the examination
is used for the differential diagnosis of AD with LBD,
normal DAT SPECT findings support the diagnosis
of AD. In some patients, a more explicit diagnosis can
be made when other molecular imaging examinations
(postsynaptic D2-receptor SPECT or PET, 18F-FDG
PET, cardiac 123I-mIBG scintigraphy, etc.) findings are
included in the interpretation.
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